OMDA Stock Risk & Deep Value Analysis
Omada Health Inc
DVR Score
out of 10
What You Need to Know About OMDA Stock
We analyzed Omada Health Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran OMDA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
OMDA Risk Analysis & Red Flags
What Could Go Wrong
Omada Health's primary risk is its ability to translate rapid revenue growth (40%+ YoY) into sustained GAAP profitability. If the company fails to consistently demonstrate operating leverage, leading to net losses continuing beyond FY2027 and accelerating cash burn beyond its current ~$211.8M cash reserves (as per Q1 2026 from previous analysis), it may need to raise additional capital through dilutive equity offerings, negatively impacting shareholder value.
Risk Matrix
Overall
Moderate
Financial
Medium
Market
Medium
Competitive
High
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Current P/S ratio of ~13.6x and P/B of 33.6x are significantly elevated for an unprofitable company, indicating high growth expectations that must be consistently met.
- ⚠
Insider selling, specifically tax-withholding dispositions by CFO Steven L. Cook (2,010 shares) and President Wei-Li Shao (noted in May 2026 reports), while routine, can be perceived as a lack of strong conviction from leadership.
- ⚠
The digital health market is highly competitive, requiring continuous innovation and clear differentiation to maintain rapid growth and avoid margin pressure from rivals like Teladoc or specialized chronic care startups.
Upcoming Risk Events
- 📅
Q2 2026 Earnings Miss (August 2026): A significant miss on revenue targets or a wider-than-expected GAAP net loss could trigger a sharp price correction and raise concerns about execution and operating leverage.
- 📅
Increased Competitive Pressure or PBM Partner Disengagement (FY2027): If a major competitor launches a superior or lower-cost integrated chronic care solution, or if a key PBM partner (e.g., Optum Rx, which typically has multi-year contracts) does not renew or significantly curtails its partnership, it could impact over 20-30% of projected revenue growth.
When to Reconsider
- 🚪
Exit if quarterly revenue growth decelerates below 25% YoY for two consecutive quarters, signaling a fundamental slowdown in market adoption or competitive inroads.
- 🚪
Sell if the company fails to demonstrate continued narrowing of GAAP net losses in subsequent earnings reports through FY2027, or if cash reserves drop below $100M without a clear path to positive operating cash flow.
Unlock OMDA Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
If Omada Health successfully leverages its strategic PBM partnerships to scale membership and drive consistent 40%+ YoY revenue growth, while simultaneously demonstrating continued operating leverage leading to sustained GAAP profitability by mid-FY2027, then its market capitalization could realistically expand to $5B-$10B within 3-5 years, representing a 5x-10x valuation re-rating from its current ~$1.06B. This is bullish because the market currently values it primarily on growth potential, and a proven path to profitability via its robust partnership network would significantly de-risk the investment thesis and attract a broader institutional investor base.
Is OMDA Stock Undervalued?
Unlock the full AI analysis for OMDA
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
OMDA Price Targets & Strategy
12-Month Target
$25.00
Bull Case
$35.00
Bear Case
$15.00
Valuation Basis
Target based on conservative application of 8x next twelve months (NTM) revenue, assuming NTM revenue of ~$370M (current run rate + growth) and reflecting analyst consensus and historical sector multiples for high-growth digital health companies nearing profitability.
Entry Strategy
Consider dollar-cost averaging in the $16.50 - $17.50 range, targeting dips towards recent support levels or the 50-day moving average (if technical data aligns).
Exit Strategy
Take 50% profit if OMDA reaches $30.00-$32.00 (approaching Morgan Stanley's previous high target). Set a stop-loss at $14.50 to protect against significant downside or fundamental shifts.
Portfolio Allocation
5-8% for an aggressive growth portfolio, given the high-risk, high-reward profile.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is OMDA Financially Healthy?
Profitability
Gross Margin
66.27%
Operating Margin
-3.69%
Net Margin
-2.22%
Return on Equity
-2.81%
EPS
$-0.11
Balance Sheet
Current Ratio
3.60
Quick Ratio
3.47
Other
Beta (Volatility)
2.13
Does OMDA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
Omada Health's moat is strengthening due to deep integrations with major PBMs, creating significant barriers to entry for competitors. These partnerships foster high switching costs and provide vast patient access, making it difficult for rivals to replicate the scale and trust built over time. Continued clinical validation of its programs will further solidify its position.
Moat Erosion Risks
- •Aggressive competition from larger, diversified healthcare technology companies (e.g., Teladoc, Oracle Health) that could develop similar or more comprehensive integrated solutions.
- •Regulatory changes in virtual care reimbursement or data privacy that could disrupt existing business models or increase compliance costs, potentially eroding profitability.
- •Failure to continuously demonstrate superior clinical outcomes and ROI to its PBM and employer clients, leading to non-renewal or reduced engagement for its subscription services.
OMDA Competitive Moat Analysis
Sign up to see competitive advantages
OMDA Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (General retail interest for high-growth small-cap digital health, but no specific trending data provided).
Institutional Sentiment
Positive (High institutional ownership at ~93.6%; analyst consensus is 'Moderate Buy' with recent 'Outperform' reiteration from Evercore post-Q1 2026 earnings).
Insider Activity (Form 4)
Mixed (CFO Steven L. Cook sold 2,010 shares ($36,040) on June 1, 2026, and President Wei-Li Shao also noted selling in May 2026, primarily for tax-withholding purposes. No open market purchases observed).
Options Flow
Normal options activity (No specific unusual activity or significant put/call ratio imbalance noted in the research).
Earnings Intelligence
Next Earnings
August 2026 (Q2 2026 Estimated)
Surprise Probability
Medium (Q1 2026 beat EPS estimates, but high-growth companies can exhibit volatility. Management previously raised FY2026 guidance, setting higher expectations.)
Historical Earnings Pattern
Q1 2026 results (May 8, 2026) were positively received (EPS beat, operating leverage noted), leading to a moderate stock price gain. Prior reactions are not explicitly detailed but typically positive for beats, negative for misses/guidance cuts.
Key Metrics to Watch
Competitive Position
Top Competitor
Teladoc Health (TDOC)
Market Share Trend
Gaining (Rapid revenue and membership growth, coupled with strategic PBM partnerships, indicates successful market penetration and share capture in its niche).
Valuation vs Peers
Omada Health trades at a higher P/S ratio (~13.6x) compared to more established, yet slower-growing, digital health peers (e.g., Teladoc trades at ~2-3x P/S), reflecting its faster growth trajectory and earlier stage of profitability.
Competitive Advantages
- •Strategic PBM Partnerships (Access to Optum Rx, Lilly Employer Connect provides significant distribution and patient reach).
- •Integrated Prescribing Capabilities (Enhances patient engagement and expands the scope of virtual care delivery).
- •Evidence-Based Programs (Focus on clinically validated outcomes for chronic condition management).
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive OMDA Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings (Expected August 2026): Continued 40%+ YoY revenue growth and further narrowing of GAAP net loss per share (consensus EPS of -$0.01 for FY2026) would signal sustained operational strength and progress towards profitability.
- •Expansion of Existing PBM Partnerships (Q3/Q4 2026): Announcement of increased membership enrollment or expanded program offerings (e.g., new chronic conditions) through Optum Rx or Lilly Employer Connect, validating demand and market penetration.
Medium-Term (6-18 months)
- •Achievement of GAAP Net Profitability (H1 2027): If Omada Health reaches positive GAAP net income for the first time by mid-2027, this would be a significant re-rating event for investors focused on sustainable business models.
- •Launch of New Prescribing Capabilities for Additional Conditions (FY2027): Introduction of prescribing capabilities beyond initial rollout for other chronic conditions, broadening market appeal and increasing patient engagement/outcomes.
Long-Term (18+ months)
- •Dominant Market Share in Digital Chronic Condition Management (FY2028-2029): If OMDA captures a leading 15-20% share of the estimated ~$50B digital chronic care market, this could drive annualized revenues to $5B-$10B.
- •Strategic Acquisition by Major Healthcare Player (FY2029-2030): Demonstrating a robust, profitable platform with strong PBM integrations positions Omada Health as an attractive target for a larger healthcare entity (e.g., health insurer, PBM, pharma company) seeking to expand its digital health footprint, potentially at a 3x-5x revenue multiple.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for OMDA?
- ✓
Monitor quarterly revenue growth; sustained rates above 35% YoY would strongly support the growth thesis.
- ✓
Track GAAP net loss per share; a consistent narrowing towards zero or positive EPS would validate operating leverage and accelerate the path to profitability.
- ✓
Look for announcements of new significant PBM partnerships or material expansions of existing ones, signaling continued market penetration and competitive advantage.
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Omada Health Inc Makes Money
Omada Health is a digital health company that offers virtual care and chronic condition management programs, focusing on conditions like diabetes, hypertension, and behavioral health. It partners with large employers, health plans, and pharmacy benefit managers (PBMs) to provide its evidence-based programs to their members, aiming to improve health outcomes and reduce healthcare costs through continuous 'virtual between-visit care.' The company provides digital tools, health coaching, and connected devices to help individuals manage their health.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Omada Health Inc (OMDA)?
As of June 12, 2026, Omada Health Inc has a DVR Score of 7.2 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Omada Health Inc?
Omada Health Inc's market capitalization is approximately $1.1B..
What is the risk level for OMDA stock?
Our analysis rates Omada Health Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is OMDA stock profitable?
Omada Health Inc has a profit margin of -2.2%. The company is currently unprofitable.
How often is the OMDA DVR analysis updated?
Our AI-powered analysis of Omada Health Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 12, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for OMDA (Omada Health Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.